354200 — NGeneBio Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩36bn
- KR₩32bn
- KR₩4bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,478 | 2,479 | 7,163 | 11,018 | 4,351 |
Cost of Revenue | |||||
Gross Profit | 742 | 928 | 2,403 | 4,142 | -139 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5,831 | 8,583 | 15,721 | 19,651 | 17,868 |
Operating Profit | -4,353 | -6,104 | -8,557 | -8,634 | -13,517 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6,846 | -8,228 | -8,431 | -9,839 | -13,175 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6,865 | -8,228 | -8,431 | -9,839 | -12,860 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -6,865 | -8,228 | -8,431 | -9,785 | -12,769 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6,865 | -8,228 | -8,431 | -9,785 | -12,769 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -555 | -674 | -695 | -781 | -1,001 |
Dividends per Share |